BRIEF published on 04/17/2026 at 21:05, 9 days 3 hours ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 9 days 3 hours ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 9 days 3 hours ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
BRIEF published on 04/13/2026 at 07:05, 13 days 17 hours ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 13 days 17 hours ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 13 days 17 hours ago Inside Information / Other news releases Innate Pharma to hold its Annual General Meeting of shareholders on May 21, 2026 at 10:30 a.m. CEST in Marseille. Shareholders must register shares by May 14, 2026, 00:00 Paris time, to attend Annual General Meeting Shareholders Registration Innate Pharma Marseille
PRESS RELEASE published on 04/13/2026 at 07:00, 13 days 17 hours ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
BRIEF published on 04/03/2026 at 07:05, 23 days 17 hours ago Innate Pharma to Join Kempen Life Sciences Conference Biotechnology Investor Meetings Innate Pharma Cancer Immunotherapies Kempen Conference
BRIEF published on 04/03/2026 at 07:05, 23 days 17 hours ago Innate Pharma will participate in the Kempen Life Sciences Conference Biotechnology Conference Innate Pharma Immunothérapies Kempen Life Sciences
PRESS RELEASE published on 04/03/2026 at 07:00, 23 days 17 hours ago Inside Information / Other news releases Innate Pharma to participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, Netherlands. The company is developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients Kempen Life Sciences Conference
Published on 04/25/2026 at 03:10, 1 day 21 hours ago BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 2 days 2 hours ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 2 days 2 hours ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 2 days 9 hours ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 2 days 9 hours ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/26/2026 at 21:15, 3 hours 19 minutes ago Changan Group Unveils Updated "Vast Ocean Plan 2.0" and Highlight Next-Generation BlueCore Hybrid at Auto China 2026
Published on 04/26/2026 at 20:15, 4 hours 19 minutes ago Safety. For Family: TIGGO9 Completes Public Three-Vehicle Composite Crash Verification During the 2026 International Business Summit
Published on 04/26/2026 at 10:20, 14 hours 14 minutes ago EQS-Adhoc: Vitruvia Medical AG: Annual Results as of December 31, 2025
Published on 04/26/2026 at 09:05, 15 hours 29 minutes ago Natural Expressions Unveils Performance 7: The Era of "Drop-and-Mow" Wireless Robotic Mowing Arrives in Europe
Published on 04/25/2026 at 16:25, 1 day 8 hours ago Leading a New Era of Family Mobility! CHERY TIGGO V, the 3-in-1 Family Vehicle, Debuts at AutoChina2026
Published on 04/24/2026 at 17:45, 2 days 6 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 2 days 7 hours ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 3 days 5 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 3 days 6 hours ago Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group
